Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

“Prostate cancer feeds on testosterone,” explains ... ADT includes medications that affect the production of LHRH: LHRH agonists and LHRH antagonists. 2. LHRH agonists and LHRH antagonists ...

A total of 542 patients had received prior HT, predominantly LHRH agonists (53.7 %); of these, 455 had received prior LHRH analogue therapy (LHRH agonists or GnRH antagonists). Baseline PSA (media ...

LHRH-a: Luteinizing hormone-releasing hormone agonist; MRC: Medical Research Council; NCIC: National Cancer Insitute of Canada; PCSS: Prostate cancer-specific survival; PSA: Prostate-specific ...

An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth Langley presented results from a phase 3 trial comparing transdermal estradiol to LHRH agonists for androgen suppression in M0 prostate cancer.

Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer ESMO 2024: Adding Metformin to ADT ...

Cases of prostate cancer are on the rise in California, according to new research. A study by UC San Francisco (UCSF) included nearly 388,000 men who had prostate cancer between 2004 and 2021.

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure. Patients with HRR-deficient metastatic ...

ADT, androgen-deprivation therapy; DOC, docetaxel; FDA, US Food and Drug Administration; mHSPC, metastatic hormone-sensitive prostate cancer; RCT, randomized controlled trial. We considered the ...

Early prostate cancer usually causes no symptoms, but can include blood in the urine or semen. The outlook is often excellent, especially if doctors diagnose it in the early stages. Prostate ...